Higher plasma vitamin D is associated with reduced risk of Clostridium difficile infection in patients with inflammatory bowel diseases

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 10, 2014, Pages 1136-1142

  Ananthakrishnan, A N ^a,b   Cagan, A ^c   Gainer, V S ^c   Cheng, S C ^d   Cai, T ^d   Szolovits, P ^e   Shaw, S Y ^a,b   Churchill, S ^f   Karlson, E W ^b,f   Murphy, S N ^a,b,d   Kohane, I ^b,f,g   Liao, K P ^b,f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PARTNERS HEALTHCARE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIFEDIOL;

ADULT; AGE DISTRIBUTION; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; RISK REDUCTION; ULCERATIVE COLITIS; VITAMIN BLOOD LEVEL;

ADULT; AGED; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK; VITAMIN D;

EID: 84898859163     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12706     Document Type: Article

References (46)

1. Issa M, Vijayapal A, Graham MB, et al,. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345-51.
2. Jen MH, Saxena S, Bottle A, et al,. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 1322-31.
3. Murthy SK, Steinhart AH, Tinmouth J, et al,. Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis. Aliment Pharmacol Ther 2012; 36: 1032-9.
4. Ananthakrishnan AN, Issa M, Binion DG,. Clostridium difficile and inflammatory bowel disease. Gastroenterol Clin North Am 2009; 38: 711-28.
5. Ananthakrishnan AN, McGinley EL, Binion DG,. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57: 205-10.
6. Ananthakrishnan AN, Guzman-Perez R, Gainer V, et al,. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 789-95.
7. Jodorkovsky D, Young Y, Abreu MT,. Clinical outcomes of patients with ulcerative colitis and co-existing clostridium difficile infection. Dig Dis Sci 2010; 55: 415-20.
8. Nguyen GC, Kaplan GG, Harris ML, et al,. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 1443-50.
9. Arif M, Weber LR, Knox JF, et al,. Patterns of proton pump inhibitor use in inflammatory bowel disease and concomitant risk of Clostridium difficile infection. Gastroenterology 2007; 132: A513.
10. Cantorna MT, Mahon BD,. D-hormone and the immune system. J Rheumatol Suppl 2005; 76: 11-20.
11. Cantorna MT, Mahon BD,. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 2004; 229: 1136-42.
12. Cantorna MT, Zhu Y, Froicu M, et al,. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004; 80: 1717S-20S.
13. Narula N, Marshall JK,. Management of inflammatory bowel disease with vitamin D: beyond bone health. J Crohns Colitis 2012; 6: 397-404.
14. Garg M, Lubel JS, Sparrow MP, et al,. Review article: vitamin D and inflammatory bowel disease-established concepts and future directions. Aliment Pharmacol Ther 2012; 36: 324-44.
15. Cantorna MT, Munsick C, Bemiss C, et al,. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 130: 2648-52.
16. Ananthakrishnan AN, Khalili H, Higuchi LM, et al,. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology 2012; 142: 482-9.
17. Ananthakrishnan AN, Cagan A, Gainer VS, et al,. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm Bowel Dis 2013; 19: 1921-7.
18. Lim WC, Hanauer SB, Li YC,. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 308-15.
19. Hing TC, Ho S, Shih DQ, et al,. The antimicrobial peptide cathelicidin modulates Clostridium difficile-associated colitis and toxin A-mediated enteritis in mice. Gut 2013; 62: 1295-305.
20. Vandamme D, Landuyt B, Luyten W, et al,. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 2012; 280: 22-35.
21. Ananthakrishnan AN, Oxford EC, Nguyen DD, et al,. Genetic risk factors for Clostridium difficile infection in ulcerative colitis. Aliment Pharmacol Ther 2013; 38: 522-30.
22. Ananthakrishnan AN, Cai T, Savova G, et al,. Improving case definition of Crohn's disease and ulcerative colitis in electronic medical records using natural language processing: a novel informatics approach. Inflamm Bowel Dis 2013; 19: 1411-20.
23. Ananthakrishnan AN, Cheng SC, Cai T, et al,. Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2013; doi. 10.1016/j.cgh.2013.10.011 [Epub ahead of print].
24. Dubberke ER, Reske KA, McDonald LC, et al,. ICD-9 codes and surveillance for Clostridium difficile-associated disease. Emerg Infect Dis 2006; 12: 1576-9.
25. Schmiedeskamp M, Harpe S, Polk R, et al,. Use of international classification of diseases, ninth revision, clinical modification codes and medication use data to identify nosocomial Clostridium difficile infection. Infect Control Hosp Epidemiol 2009; 30: 1070-6.
26. Shaklee J, Zerr DM, Elward A, et al,. Improving surveillance for pediatric Clostridium difficile infection: derivation and validation of an accurate case-finding tool. Pediatr Infect Dis J 2011; 30: e38-40.
27. Charlson ME, Pompei P, Ales KL, et al,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
28. Chakraborty K, Maity PC, Sil AK, et al,. cAMP stringently regulates human cathelicidin antimicrobial peptide expression in the mucosal epithelial cells by activating cAMP-response element-binding protein, AP-1, and inducible cAMP early repressor. J Biol Chem 2009; 284: 21810-27.
29. Schwalfenberg GK,. A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency. Mol Nutr Food Res 2011; 55: 96-108.
30. Tai EK, Wu WK, Wong HP, et al,. A new role for cathelicidin in ulcerative colitis in mice. Exp Biol Med (Maywood) 2007; 232: 799-808.
31. Giesemann T, Guttenberg G, Aktories K,. Human alpha-defensins inhibit Clostridium difficile toxin B. Gastroenterology 2008; 134: 2049-58.
32. Gombart AF, Bhan I, Borregaard N, et al,. Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis 2009; 48: 418-24.
33. Youssef D, Bailey B, El Abbassi A, et al,. Healthcare costs of Staphylococcus aureus and Clostridium difficile infections in veterans: role of vitamin D deficiency. Epidemiol Infect 2010; 138: 1322-7.
34. Quraishi SA, Litonjua AA, Moromizato T, et al,. Association between prehospital vitamin D status and hospital-acquired Clostridium difficile infections. JPEN J Parenter Enteral Nutr 2014; PMID: 24492311 [Epub ahead of print].
35. van der Wilden GM, Fagenholz PJ, Velmahos GC, et al,. Vitamin D status and severity of Clostridium difficile infections: a prospective cohort study in hospitalized adults. JPEN J Parenter Enteral Nutr 2014; PMID: 24408036 [Epub ahead of print].
36. Wang WJ, Gray S, Sison C, et al,. Low vitamin D level is an independent predictor of poor outcomes in Clostridium difficile-associated diarrhea. Therap Adv Gastroenterol 2014; 7: 14-9.
37. Schneeweiss S, Korzenik J, Solomon DH, et al,. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009; 30: 253-64.
38. Powell N, Jung SE, Krishnan B,. Clostridium difficile infection and inflammatory bowel disease: a marker for disease extent? Gut 2008; 57: 1183-4; author reply 1184.
39. Issa M, Weber LR, Skaros S, et al,. Decreasing rates of colectomy despite high rates of hospitalization in C difficie. infection IBD patients: a tertiary referral center experience. Gastroenterology 2007; 132: A663.
40. Dial S, Alrasadi K, Manoukian C, et al,. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171: 33-8.
41. Dial S, Delaney JA, Barkun AN, et al,. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-95.
42. Ananthakrishnan AN,. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011; 8: 17-26.
43. Nseir W, Bishara J, Mograbi J, et al,. Do statins protect against the development of Clostridium difficile-associated diarrhoea? J Antimicrob Chemother 2013; 68: 1889-93.
44. Motzkus-Feagans CA, Pakyz A, Polk R, et al,. Statin use and the risk of Clostridium difficile in academic medical centres. Gut 2012; 61: 1538-42.
45. Joseph AJ, George B, Pulimood AB, et al,. 25 (OH) vitamin D level in Crohn's disease: association with sun exposure & disease activity. Indian J Med Res 2009; 130: 133-7.
46. Hata TR, Kotol P, Jackson M, et al,. Administration of oral vitamin D induces cathelicidin production in atopic individuals. J Allergy Clin Immunol 2008; 122: 829-31.